多发性骨髓瘤的风险分层治疗展望。
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
机构信息
Perlmutter Cancer Center, NYU Langone, New York, New York.
Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom.
出版信息
Blood Cancer Discov. 2022 Jul 6;3(4):273-284. doi: 10.1158/2643-3230.BCD-21-0205.
Abstract
The multiple myeloma treatment landscape has changed dramatically. This change, paralleled by an increase in scientific knowledge, has resulted in significant improvement in survival. However, heterogeneity remains in clinical outcomes, with a proportion of patients not benefiting from current approaches and continuing to have a poor prognosis. A significant proportion of the variability in outcome can be predicted on the basis of clinical and biochemical parameters and tumor-acquired genetic variants, allowing for risk stratification and a more personalized approach to therapy. This article discusses the principles that can enable the rational and effective development of therapeutic approaches for high-risk multiple myeloma.
摘要
多发性骨髓瘤的治疗格局已经发生了巨大变化。这种变化伴随着科学知识的增加，使得生存得到了显著改善。然而，临床结果仍然存在异质性，一部分患者不能从当前的治疗方法中获益，预后仍然较差。基于临床和生化参数以及肿瘤获得的遗传变异，可以预测结果的很大一部分变异性，从而实现风险分层和更个性化的治疗方法。本文讨论了能够使高危多发性骨髓瘤的治疗方法得到合理和有效发展的原则。
相似文献
1
Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.多发性骨髓瘤的风险分层治疗展望。
Blood Cancer Discov. 2022 Jul 6;3(4):273-284. doi: 10.1158/2643-3230.BCD-21-0205.
2
New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma.多发性骨髓瘤诊断、预后及反应评估的新进展
Clin Cancer Res. 2016 Nov 15;22(22):5428-5433. doi: 10.1158/1078-0432.CCR-16-0866.
3
The use of molecular-based risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma.基于分子的风险分层和药物基因组学在多发性骨髓瘤的预后预测和个体化治疗管理中的应用。
Int J Hematol. 2011 Oct;94(4):321-333. doi: 10.1007/s12185-011-0948-y. Epub 2011 Oct 15.
4
Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma.疾病异质性、预后评估及靶向治疗在多发性骨髓瘤中的作用
Leuk Lymphoma. 2021 Dec;62(13):3087-3097. doi: 10.1080/10428194.2021.1957875. Epub 2021 Jul 24.
5
Biologic frontiers in multiple myeloma: from biomarker identification to clinical practice.多发性骨髓瘤的生物学前沿：从生物标志物识别到临床实践
Clin Cancer Res. 2014 Feb 15;20(4):804-13. doi: 10.1158/1078-0432.CCR-13-2159. Epub 2013 Nov 22.
6
IMWG consensus on risk stratification in multiple myeloma.IMWG 共识：多发性骨髓瘤的风险分层。
Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26.
7
Genomics in multiple myeloma: biology and clinical implications.多发性骨髓瘤中的基因组学：生物学与临床意义
Pharmacogenomics. 2005 Sep;6(6):563-73. doi: 10.2217/14622416.6.6.563.
8
New prognostic biomarkers in multiple myeloma.多发性骨髓瘤中的新型预后生物标志物。
Postepy Hig Med Dosw (Online). 2016 Jan 4;70(0):811-9. doi: 10.5604/17322693.1211183.
9
Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic.通过将遗传学和生物学进展融入临床来维持多发性骨髓瘤的治疗进展。
Expert Rev Hematol. 2018 Jul;11(7):513-523. doi: 10.1080/17474086.2018.1489718. Epub 2018 Jun 26.
10
Treatment of newly diagnosed multiple myeloma: advances in current therapy.初诊多发性骨髓瘤的治疗：当前疗法的进展。
Med Oncol. 2010 Jun;27 Suppl 1:S14-24. doi: 10.1007/s12032-009-9370-1. Epub 2009 Dec 25.
引用本文的文献
1
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma.来那度胺维持治疗多发性骨髓瘤期间及停药后克隆性造血的演变
Leukemia. 2025 Jul 16. doi: 10.1038/s41375-025-02707-2.
2
MAMDC2-AS1 Induces Cuproptosis in Relapsed and Refractory Multiple Myeloma.MAMDC2-AS1在复发难治性多发性骨髓瘤中诱导铜死亡
Cancer Rep (Hoboken). 2025 May;8(5):e70216. doi: 10.1002/cnr2.70216.
3
End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy.CD38与免疫治疗时代多发性骨髓瘤患者的终末期管理
Front Oncol. 2024 Oct 31;14:1436587. doi: 10.3389/fonc.2024.1436587. eCollection 2024.
4
Unravelling Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treatment in Real-World Practice in Spain: The CARINAE Study.探索西班牙真实世界实践中不符合移植条件的新诊断多发性骨髓瘤的治疗：CARINAE研究
Pharmaceuticals (Basel). 2024 Sep 26;17(10):1272. doi: 10.3390/ph17101272.
5
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.一项单细胞图谱描绘了与多发性骨髓瘤预后相关的骨髓免疫微环境失调情况。
bioRxiv. 2024 May 17:2024.05.15.593193. doi: 10.1101/2024.05.15.593193.
6
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features.多维尺度分析技术揭示多发性骨髓瘤患者中存在 gain1q 和 loss13q 共发生现象，这些患者具有特定的基因组、转录组和不良临床特征。
Nat Commun. 2024 Feb 20;15(1):1551. doi: 10.1038/s41467-024-45000-z.
7
Novel Anti-B-cell Maturation Antigen Alpha-Amanitin Antibody-drug Conjugate HDP-101 Shows Superior Activity to Belantamab Mafodotin and Enhanced Efficacy in Deletion 17p Myeloma Models.新型抗B细胞成熟抗原α-鹅膏蕈碱抗体药物偶联物HDP-101在17p缺失骨髓瘤模型中显示出优于贝兰他单抗马福汀的活性和增强的疗效。
Res Sq. 2024 Jan 11:rs.3.rs-3843028. doi: 10.21203/rs.3.rs-3843028/v1.
8
A rational approach to functional high-risk myeloma.理性对待功能性高危骨髓瘤。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):433-442. doi: 10.1182/hematology.2023000443.
9
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions.根据其他基因损伤的存在情况，探讨14号与16号染色体易位t(14;16)在多发性骨髓瘤中的预后影响。
Blood Cancer J. 2023 Oct 26;13(1):160. doi: 10.1038/s41408-023-00933-4.
10
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling.功能性高危多发性骨髓瘤的定义因素和驱动因素：来自基因组、转录组和免疫分析的见解
Front Oncol. 2023 Oct 2;13:1240966. doi: 10.3389/fonc.2023.1240966. eCollection 2023.
本文引用的文献
1
Genomic characterization of functional high-risk multiple myeloma patients.功能高危多发性骨髓瘤患者的基因组特征分析。
Blood Cancer J. 2022 Jan 31;12(1):24. doi: 10.1038/s41408-021-00576-3.
2
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.克隆性和亚克隆性TP53分子损伤与多发性骨髓瘤的预后和进展相关。
Blood Cancer J. 2022 Jan 26;12(1):15. doi: 10.1038/s41408-022-00610-y.
3
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma.基于肿瘤和免疫生物标志物的机器学习模型预测多发性骨髓瘤中不可检测的微小残留病和生存结局。
Clin Cancer Res. 2022 Jun 13;28(12):2598-2609. doi: 10.1158/1078-0432.CCR-21-3430.
4
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.达雷妥尤单抗、卡非佐米、来那度胺和地塞米松联合最小残留病灶反应适应性治疗新诊断多发性骨髓瘤。
J Clin Oncol. 2022 Sep 1;40(25):2901-2912. doi: 10.1200/JCO.21.01935. Epub 2021 Dec 13.
5
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.原发性浆细胞白血病：国际骨髓瘤工作组根据外周血浆细胞百分比的共识定义。
Blood Cancer J. 2021 Dec 2;11(12):192. doi: 10.1038/s41408-021-00587-0.
6
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics.单细胞转录组学揭示难治性多发性骨髓瘤中亚克隆特异性的微环境影响和药物反应。
Nat Commun. 2021 Nov 29;12(1):6960. doi: 10.1038/s41467-021-26951-z.
7
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.isatuximab、卡非佐米、来那度胺和地塞米松（Isa-KRd）用于高危多发性骨髓瘤的一线治疗：GMMG-CONCEPT试验的中期分析
Leukemia. 2022 Mar;36(3):885-888. doi: 10.1038/s41375-021-01431-x. Epub 2021 Nov 3.
8
Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.硼替佐米通过激活 cGAS/STING 通路诱导抗多发性骨髓瘤免疫反应。
Blood Cancer Discov. 2021 Sep;2(5):468-483. doi: 10.1158/2643-3230.BCD-21-0047. Epub 2021 Apr 23.
9
High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse.多发性骨髓瘤中的高风险转录谱是一种后天获得的特征，可出现在任何亚型中，且在每次后续复发时更频繁出现。
Br J Haematol. 2021 Oct;195(2):283-286. doi: 10.1111/bjh.17670. Epub 2021 Jul 9.
10
Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length.利用获得性基因特征、克隆性造血和端粒长度改善老年多发性骨髓瘤患者的预后评估
Leukemia. 2022 Jan;36(1):221-224. doi: 10.1038/s41375-021-01320-3. Epub 2021 Jun 19.
Zotero 插件